# An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

> **NCT01573910** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 985 (actual)

## Conditions studied

- Bacterial Conjunctivitis

## Interventions

- **DRUG:** Moxifloxacin ophthalmic solution, 0.5%
- **DRUG:** Ofloxacin ophthalmic solution, 0.3%

## Key facts

- **NCT ID:** NCT01573910
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 985 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01573910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01573910, "An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01573910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*